Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia

Am J Hematol. 2021 Nov 1;96(11):E433-E436. doi: 10.1002/ajh.26334. Epub 2021 Sep 12.

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
² Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.
³ Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, USA.

PMID: 34428328
DOI: 10.1002/ajh.26334

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Blast Crisis / drug therapy*
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Female
Humans
Leukemia, Myelomonocytic, Chronic / drug therapy*
Male
Middle Aged
Sulfonamides / therapeutic use*
Treatment Outcome

Substances

Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
venetoclax